New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations-Reference-Cited by-同舟云学术

New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations

Published:2014-01-28 Issue:11 Volume:135 Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Bleau Anne-Marie¹,Freire Javier¹²,Pajares María José¹²,Zudaire Isabel¹,Anton Iker¹,Nistal-Villán Estanislao³,Redrado Miriam¹,Zandueta Caroli na¹,Garmendia Irati¹²,Ajona Daniel¹,Blanco David¹,Pio Ruben¹⁴,Lecanda Fernando¹,Calvo Alfonso¹²,Montuenga Luis M.¹²

Affiliation:

1. Division of Oncology; Center for Applied Medical Research (CIMA); University of Navarra; Pamplona Spain

2. Department of Histology and Pathology; School of Medicine; University of Navarra; Pamplona Spain

3. Division of Hepatology and Gene Therapy; CIMA, University of Navarra; Pamplona Spain

4. Department of Biochemistry; School of Medicine; University of Navarra; Pamplona Spain

Funder

EU 7th Framework FP72007-2013

Narie Curie Grant

RTICC

Spanish Minstry of Economy and Competitiveness

UTE-CIMA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.28574/fullpdf

Reference46 articles.

1. Cancer statistics, 2009. CA;Jemal;Cancer J Clin,2009

2. SnapShot: non-small cell lung cancer;Heist;Cancer Cell,2012

3. Mouse models for human lung cancer;Meuwissen;Genes Dev,2005

4. Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment;Freire;Neoplasia,2013

5. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer;Bednarek;Cancer Res,2000

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer;EMBO reports;2023-06-27

2. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer;Cancer Cell;2022-10

3. Potent clinical predictive and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer;2022-06-17

4. Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity;Frontiers in Oncology;2022-03-09

5. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation;Journal for ImmunoTherapy of Cancer;2021-03